TSAAI 2024 Annual Meeting

Pigeon Forge, TN US
August 9, 2024 to August 11, 2024

The Tennessee Society of Allergy, Asthma and Immunology (TSAAI) was established to coordinate the efforts of specialists in allergy, asthma and immunology in the state of Tennessee, principally for scientific and education purposes and to promote the highest standards of practitioners in the fields of allergy, asthma and immunology.TSAAI's annual educational meeting consists of presentations by recognized speakers in the field of allergy, asthma and immunology.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and the Tenessee Society of Allergy, Asthma & Immunology (TSAAI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…
1. Choose an affordable inhaler for most patients and recognize which biologic to choose for the right patient.
2. Understand when and how to workup difficult HAE patient cases. Become updates in education to better diagnose and treat patients with HAE.
3. Recognize novel therapeutic strategies for IgE-mediated food allergy.
4. Appreciate the nature of IgE-mediated and non-IgE-mediated adverse reactions to various vaccines.
5. Perform differential diagnosis of eosinophilic disorders and use appropriate management for these patients.
6. Understand the management of urticaria and prepare for new therapies coming in the future.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Course opens: 
08/09/2024
Course expires: 
08/11/2025
Event starts: 
08/09/2024 - 3:00pm CDT
Event ends: 
08/11/2024 - 11:30am CDT
Rating: 
0

TSAAI 2024 Annual Meeting
Dollywood’s HeartSong Conference Center, Pigeon Forge, TN
August 9-11, 2024

Friday, August 9, 2024

3:30 – 5:00 pm Exhibitor setup
Conference Center

4:00 – 5:00 pm Attendee Early Check-In (Optional)
Conference Center Hallway

6:15 – 7:10 pm Welcome reception sponsored by CSL Behring (Non-CME)
Heartsong Breezeway

7:15 – 8:15 pm Product Theatre Dinner provided by CSL Behring - Non-CME
“Exploring the Burden and Management of Hereditary Angioedema: Optimizing Long-Term Prophylaxis From the Start”, John Anderson, MD
Heartsong Breezeway

Saturday, August 10, 2024

7:15 – 7:45 am Attendee Check-In

7:15 – 7:45 am Breakfast & exhibits

7:45 – 8:00 am Introduction, Ty Prince, MD

8:00 – 9:00 am The Masqueraders of Asthma, Nina Ramirez, MD

9:00 – 10:00 am Hereditary Angioedema: Where Are We Now?, Marc Riedl, MD

10:00 – 10:30 am Break & exhibits    

10:30 – 11:30 am Evaluation and Management of Adverse Reactions to Vaccines, John Kelso, MD

11:30 – 12:30 pm The Latest in Food Allergy Therapy, Jay Leiberman, MD

1:00 pm    Non-CME Lunch & Learn provided by Takeda

Sunday, August 11, 2024

7:15 – 8:00 am Breakfast & exhibits

8:00 – 9:00 am What the VUS?!: A Case-Based, Interactive, Practical Approach to VUS Results on Genetic Testing, Monica Lawrence, MD

9:00 – 10:00 am Evaluation of Eosinophilia, Princess Ogbogu, MD

10:00 – 10:30 am Break & exhibits

10:30 – 11:30 am Chronic Urticaria: Mechanism, Management and New Therapeutics, Farnaz Tabatabaian, MD
and Q & A

11:30 am Meeting adjourn
*please stay for a short business meeting & door prize drawing!

Dollywood HeartSong Conference Center
1210 Dollywood Resorts Blvd
Pigeon Forge, TN 37863
United States

All relevant financial relationships with ineligible companies have been mitigated.

Monica Lawrence, MD, Speaker
Consultant: Premier Research; Researcher: Takeda

Jay Lieberman, MD, Speaker
Advisor: ARS, Aquestive, Bryn; Researcher: DBV

Princess Ogbogu, MD, Speaker
Advisor: AstraZeneca; Consultant: AstraZeneca; Researcher: AstraZeneca, GSK, Blueprint 

Tidence Prince, MD, Program Chair and Planner
Speaker: CSL Behring

Nina Ramirez, MD, Speaker
Advisor: AstraZeneca, Sanofi Regeneron, Amgen; Speaker: AstraZeneca, Sanofi Regeneron

Marc Riedl, MD MS, Speaker
Consultant: Biomarin, Biocryst, CSL Behring, Kalvista, Pharvaris, Takeda, Astria, Celldex, Cycle Pharmacy, Grifols, Intellia, Pfizer, Pharming, Sanofi-Regeneron; Researcher: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Pharvaris, Takeda; Speaker: CSL Behring, Takeda, Grifols, Pharming

Farnaz Tabatabaian, MD, Speaker
Advisor: Blueprint, Cogent, Sanofi; Speaker: Blueprint, Sanofi; Researcher: Cogent

The following have no relevant financial relationships with ineligible companies to disclose:

John Kelso, MD, Speaker
Karthik Krishnan, MD, Program Chair and Planner
Michelle Kittle, Meeting Coordinator
Chloe Miller, Meeting Coordinator    

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Please login or create an account to take this course.